Buscar
Black Diamond Therapeutics Inc
BDTXAñadir a la lista de seguimiento
1.885USD
-0.015-0.79%
Horarios del mercado 09/24, 13:03（ET）
108.01MCap. mercado
PérdidaP/E TTM
Acerca de Black Diamond Therapeutics Inc Compañía
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Perfil de Black Diamond Therapeutics Inc
Símbolo de cotizaciónBDTX
Nombre de la empresaBlack Diamond Therapeutics Inc
Fecha de salida a bolsaJan 30, 2020
Director ejecutivoVelleca (Mark A)
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección245 First Street, 18Th Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono16174175868
Sitio Webhttps://www.blackdiamondtherapeutics.com/
Símbolo de cotizaciónBDTX
Fecha de salida a bolsaJan 30, 2020
Director ejecutivoVelleca (Mark A)
Ejecutivos de Black Diamond Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
51.84K
+13.12%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
110.24K
+6.99%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Black Diamond Therapeutics Inc?
Los cinco principales accionistas de Black Diamond Therapeutics Inc son: Dr. Ali Behbahani, M.D.
¿Cuántas instituciones poseen acciones de Black Diamond Therapeutics Inc (BDTX)?
A fecha de 2026Q1, 265 instituciones poseen acciones de Black Diamond Therapeutics Inc, con un valor de mercado combinado de aproximadamente 45.02M, lo que representa el 78.72% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -14972289.00.